Sirona Dental Systems files prospectus supplement to its existing shelf registration statement

NewsGuard 100/100 Score

Sirona Dental Systems, Inc. (“Sirona”) (Nasdaq:SIRO), today announced that it is filing a prospectus supplement to its existing shelf registration statement with the U.S. Securities and Exchange Commission relating to an underwritten public offering by Sirona Holdings Luxco S.C.A. of 7,000,000 shares of its common stock and 250,000 shares by Jeffery Slovin. Sirona Dental Systems, Inc. will not receive any proceeds from this sale of its common stock. One of the selling stockholders, Sirona Holdings Luxco S.C.A., has also granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock.

Barclays Capital Inc. is the sole underwriter of the offering. The offering will be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained from:

Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; [email protected] (phone: 888-603-5847). A copy of the prospectus supplement and accompanying base prospectus when filed may also be obtained at no charge at the U.S. Securities and Exchange Commission's website, at http://www.sec.gov.

SOURCE Sirona Dental Systems, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.